The mobile gaming company from Herzliya has started the IPO process, but no details are available yet.
Shareholders have reason to regret Mylan's rejection of Teva's $40 billion offer, Perrigo's rejection of Mylan's $26 billion offer, and Teva's $40 billion acquisition of Actavis.